# Mounjaro: what it is, and the honest evidence

> What Mounjaro actually is: the molecule (tirzepatide, a dual GLP-1/GIP agonist), what it’s FDA-approved for, how it differs from Zepbound and from Ozempic, and honest, evidence-graded answers on side effects and the myths.

**Type:** Brand hub · **Molecule:** tirzepatide · **Maker:** Eli Lilly · **Source page:** https://thepeptideera.com/mounjaro

## At a glance
Mounjaro is a brand name for tirzepatide, a dual GLP-1 and GIP receptor agonist made by Eli Lilly and FDA-approved for type 2 diabetes. Unlike semaglutide (Ozempic/Wegovy), which targets one gut-hormone receptor, tirzepatide targets two. It is the same molecule as Zepbound, which carries the chronic-weight-management and obstructive-sleep-apnea indications.

## Facts
- **Molecule:** tirzepatide
- **How it works:** a dual GLP-1 and GIP receptor agonist
- **Maker:** Eli Lilly
- **Form:** a once-weekly injection
- **FDA-approved for:** type 2 diabetes
- **Sibling brand:** Zepbound — the same molecule, approved for weight management and sleep apnea

## Evidence
- [Mounjaro vs. Zepbound: same molecule, two different labels](https://thepeptideera.com/evidence/mounjaro-vs-zepbound) — Same molecule, two brands — Mounjaro vs Zepbound, explained.
- [Tirzepatide side effects: what the evidence actually shows](https://thepeptideera.com/evidence/tirzepatide-side-effects) — What the evidence shows about tirzepatide’s side effects.
- [Semaglutide vs tirzepatide: how they really compare](https://thepeptideera.com/evidence/semaglutide-vs-tirzepatide) — How the dual-agonist compares with semaglutide.
- [Can a GLP-1 treat fatty liver disease (MASH)?](https://thepeptideera.com/evidence/glp1-and-fatty-liver) — The fatty-liver (MASH) question people ask about tirzepatide.
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the brand decoder](https://thepeptideera.com/evidence/glp1-brand-decoder) — The full four-brand, two-molecule map.
- [GLP-1 cost and access in 2026: how pricing and coverage work](https://thepeptideera.com/evidence/glp1-cost-and-access) — How pricing and coverage actually work in 2026.

## Myths, graded
- "Zepbound and Mounjaro are different drugs." — Same molecule — both are tirzepatide; the two brands exist because the drug is approved (and marketed) for different uses. (https://thepeptideera.com/myths/zepbound-mounjaro-different-drugs)
- "Tirzepatide is just a stronger version of Ozempic." — Partly true, oversimplified (https://thepeptideera.com/myths/tirzepatide-just-stronger)
- "Tirzepatide (Mounjaro/Zepbound) is FDA-approved to treat fatty liver disease (MASH)." — False — semaglutide (Wegovy) is the GLP-1 approved for MASH; tirzepatide isn't (still investigational). (https://thepeptideera.com/myths/tirzepatide-approved-for-fatty-liver)
- "GLP-1s paralyze your stomach and give you gastroparesis." — Partly true, oversimplified (https://thepeptideera.com/myths/glp1-gastroparesis)
- "GLP-1s cause thyroid cancer." — Misleading overstatement (https://thepeptideera.com/myths/thyroid-cancer)

## Sources (2)
1. MOUNJARO (tirzepatide) injection — FDA Prescribing Information (DailyMed) — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0 [LABEL]
2. ZEPBOUND (tirzepatide) injection — FDA Prescribing Information (DailyMed) — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b [LABEL]

---
From The Peptide Era (https://thepeptideera.com) — evidence-graded, primary-sourced answers about GLP-1 medicines. Education, not medical advice. Not a buying guide. No doses, no sourcing.